In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in ...

Oppenheimer analyst Leland Gershell raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $8 and keeps an Outperform rating on the ...

New findings published in Nature Medicine showed that people can enter prediabetes remission — and lower type 2 diabetes risk — even without weight loss. These findings could help motivate patients ...

Patient education conversations emphasize 3 core elements: equivalent efficacy supported by rigorous pharmacokinetic and ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

The FDA has approved a once-monthly injection of Eli Lilly’s Omvoh for maintenance therapy in adult patients with moderately ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...